Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 5Breast 3Thoracic 2Genitourinary 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1NET 1Head & Neck 1Gastrointestinal 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Lung Neoplasms 1

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Poly(ADP-ribose) Polymerase Inhibitors × Thoracic × Clear all
NCT05392686 2022-05-26

PD1 and PARP for Maintenance Therapy in NSLLC

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
52 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT03227016 2021-01-27

Study in Patients With SCLC of Veliparib in Combination With Topotecan

Central European Society for Anticancer Drug Research

Phase 1 Unknown
30 enrolled
Thoracic

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡